Prescription medicine
Tafluprost Brand names: Zioptan
Tafluprost (Zioptan) is a prescription medicine with an FDA approval on record since 2012. FDA's NDC Directory lists it from 3 generic labelers, and pharmacies paid $2.45 per unit (Tafluprost 0.0015% eye drop) in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the tafluprost FDA label on DailyMed (effective April 23, 2026, Thea Pharma Inc.); the NDA 202514 record on Drugs@FDA; every tafluprost label on DailyMed.
Highlights of the record
FDA label of April 23, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageZIOPTAN® is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Forms and strengths
- 0.0045 mg/.3ml
- 0.015 mg/ml
Solution/ drops.
On the market
- Earliest approval on file
- February 10, 2012 Zioptan, Thea Pharma; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 3 first August 19, 2019; 3 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 5 of which 3 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- May 28, 2029 Zioptan solution/drops; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $2.45 per unit Tafluprost 0.0015% eye drop
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 2,906 through July 30, 2026
What is tafluprost used for?
From the label: indications and usageZIOPTAN® is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. ZIOPTAN is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Conditions named in the indications of tafluprost's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Prostaglandin Analog.
Source: FDA drug label (ZIOPTAN), Thea Pharma Inc., effective April 23, 2026 (SPL set db529b54-2ac7-4020-9791-7333bbe6c90f), via openFDA; the full label on DailyMed
Is there a generic for tafluprost (Zioptan)?
The FDA approved the first generic tafluprost on August 19, 2019. 3 generic applications are approved; 3 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists tafluprost from 3 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists 2 patents for Zioptan solution/drops, the last expiring on May 28, 2029. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2012 earliest approval on file
- 2019 first generic approved
- 2029 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for tafluprost (Zioptan)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $2.45 per unit (Tafluprost 0.0015% eye drop), down 16% from $2.92 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Tafluprost 0.0015% eye drop (generic)
- Zioptan 0.0015% eye drop (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Tafluprost 0.0015% eye drop | Generic | $2.45 per unit | n/a | -16% |
| Zioptan 0.0015% eye drop | Brand | $8.49 per unit | n/a | -0.1% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for tafluprost?
The FDA Adverse Event Reporting System holds 2,906 reports that list tafluprost among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 330 are coded as a death and 287 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as tafluprost?
17 other medicines are given the same way (ophthalmic) and in the same FDA class as tafluprost or labeled mainly for the same use (glaucoma), the same class first. Glaucoma lists all 20 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (ophthalmic) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Bimatoprost | Glaucoma | 13 labelers | $6.97 per mL 0.03% eye drops | No current entry |
| Latanoprost | Glaucoma | 14 labelers | $1.58 per mL 0.005% eye drops | No current entry |
| Travoprost | Glaucoma | 11 labelers | $9.07 per mL 0.004% eye drop | A presentation being discontinued |
| Latanoprost and netarsudil | Glaucoma | none listed | $139.40 per mL 0.02%-0.005% eye drp | No current entry |
| Timolol | Glaucoma | 21 labelers | $0.774 per mL 0.5% eye drops | No current entry |
| Brimonidine | Glaucoma | 12 labelers | $9.06 per mL 0.1% drop | No current entry |
| Dorzolamide and timolol | Glaucoma | 14 labelers | $0.893 per mL Dorzolamide-timolol eye drops | No current entry |
| Brimonidine and timolol | Glaucoma | 14 labelers | $2.15 per mL 0.2%-0.5% | No current entry |
Every medicine labeled for the same conditions as tafluprost
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does tafluprost compare with medicines for the same use?
1 side-by-side page set tafluprost beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to tafluprost
- 17 medicines for the same use
- Other prostaglandin analogs
- the pharmacologic class, with prices and generics
- Tafluprost side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other